Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MNPR
Stock Latest News
Company Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
2d ago
8K
MNPR
Premium
Ratings
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
6d ago
MNPR
Premium
Company Announcements
Monopar Highlights Strong Phase 3 Data for ALXN1840
1M ago
8K
MNPR
Premium
Ratings
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
1M ago
MNPR
Premium
The Fly
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
1M ago
MNPR
Premium
Ratings
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
2M ago
MNPR
Premium
Pre-Earnings
MNPR Upcoming Earnings Report: What to Expect?
2M ago
MNPR
Premium
Company Announcements
Monopar Appoints Chief Commercial and Strategy Officer Rodriguez
3M ago
8K
MNPR
Premium
The Fly
Monopar Therapeutics appoints Susan Rodriguez as CCSO
3M ago
MNPR
Premium
Ratings
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
4M ago
MNPR
Premium
Market News
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
4M ago
ENGN
MNPR
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
4M ago
CYTK
MNPR
Premium
The Fly
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
4M ago
MNPR
Premium
Ratings
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
4M ago
MNPR
Premium
Ratings
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
6M ago
MNPR
Premium
The Fly
Monopar downgraded to Outperform from Strong Buy at Raymond James
6M ago
MNPR
Premium
Company Announcements
Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
6M ago
MNPR
Premium
The Fly
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
6M ago
MNPR
Premium
Ratings
Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
6M ago
MNPR
Premium
The Fly
Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
6M ago
JD
FUN
Premium
Company Announcements
Monopar Therapeutics Unveils Promising Phase 2 Study Results
6M ago
8K
MNPR
Premium
The Fly
Monopar Therapeutics initiated with an Outperform at Leerink
6M ago
MNPR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
